1 / 26

Osteoprosis

Osteoprosis. Haya M. Al- Malaq , Msc Lecturer Clinical Pharmacy Department Haya_malak@yahoo halmalaq@ksu.edu.sa. Defenition. Osteoporosis is a skeletal disorder characterized by compromised bone strength predisposing individuals to an increased fracture risk. Categories .

cissy
Télécharger la présentation

Osteoprosis

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Osteoprosis Haya M. Al-Malaq, Msc Lecturer Clinical Pharmacy Department Haya_malak@yahoo halmalaq@ksu.edu.sa

  2. Defenition • Osteoporosis is a skeletal disorder characterized by compromised bone strength predisposing individuals to an increased fracture risk.

  3. Categories • postmenopausal osteoporosis, • age related steoporosis • secondary osteoporosis.

  4. Pathophysiology • Bone loss occurs when bone resorption exceeds bone formation, usually from high bone turnover when the number and/or depth of bone resorption sites greatly exceed the rate and ability of osteoblasts to form new bone. • In addition to reduced bone mineral density (BMD), bone quality and structural integrity are impaired because of the increased quantity of immature bone that is not yet adequately mineralized. • Men and women begin to lose a small amount of bone mass starting in the third or fourth decade as a consequence of reduced bone formation. • Estrogen deficiency during menopause increases proliferation, differentiation, and activation of new osteoclasts and prolongs survival of mature osteoclasts; this increases bone resorption more than formation. • Men do not undergo a period of accelerated bone resorption similar to menopause. • The etiology of male osteoporosis is multifactorial; secondary causes and aging are the most common contributing factors. • Age-related osteoporosis occurs mainly because of hormone, calcium, and vitamin D deficiencies leading to accelerated bone turnover and reduced osteoblast formation. • Drug-induced osteoporosis may result from systemic corticosteroids (prednisone doses greater than 7.5 mg/day), thyroid hormone replacement, some antiepileptic drugs (e.g., phenytoin, phenobarbital), depot medroxyprogesterone acetate, and other agents.

  5. Clinical presentation • Many patients are unaware that they have osteoporosis and only present after fracture. Fractures can occur after bending, lifting, or falling, or independent of any activity. • The most common osteoporosis-related fractures involve the vertebrae, proximal femur, & wrist. 2/3 of patients with vertebral fractures are asymptomatic; the remainder present with moderate to severe back pain that radiates down a leg after a new vertebral fracture. The pain usually subsides significantly after 2 to 4 wks, but chronic, low-back pain may persist. • Multiple vertebral fractures decrease height & sometimes curve the spine with or without significant back pain.

  6. Clinical presentation • Patients with a non vertebral fracture frequently present with severe pain, swelling, & reduced function & mobility at the fracture site.

  7. Diagnosis • History • Major risk factor (<127 lb in postmenopausal women), history of osteoporotic fracture in a first-degree relative, and personal history of low-trauma fracture as an adult. age, high bone turnover, low BMI index (<19 kg/m2), RA, & glucocorticoid use. • Complete physical examination • BMD of central hip & spine • T score: Normal bone mass is a T-score greater than –1, osteopenia is –1 to –2.4, & osteoporosis is at or below –2.5. • low trauma fracture

  8. Desired outcome • The primary goal of osteoporosis management is prevention. • Optimizing skeletal development & peak bone mass accrual in childhood, adolescence, and early adulthood will reduce the future incidence of osteoporosis. • Once osteopenia or osteoporosis develops, the objective is to stabilize or improve bone mass and strength and prevent fractures. • Goals in patients who have already suffered osteoporotic fractures include reducing future falls and fractures, improving functional capacity, reducing pain and deformity, and improving quality of life.

  9. Treatment

  10. Non-Pharmacologicla • balanced diet with adequate intake of calcium & vitamin D or , calcium supplements. • caffeine increases calcium excretion, caffeine intake should be limited to two servings per day. • Smoking cessation • Weight-bearing aerobic and strengthening exercises improving muscle strength, coordination, balance, & mobility.

  11. Pharmacologic therapy

  12. Antiresorptive

  13. Antiresorptive

  14. Antiresorptive

  15. Antiresorptive

  16. Antiresorptive

  17. Antiresorptive

  18. Antiresorptive

  19. Anabolic therapy

  20. Anabolic therapy

  21. Anabolic therapy

  22. Glucocorteciods-induced osteoprosis • Guidelines for managing corticosteroid-induced osteoporosis recommend measuring BMD at the beginning of chronic therapy (prednisone 5 mg or more daily or equivalent for at least 6 months) and follow up monitoring with DXA in 6 to 12 months. BMD should be measured in patients taking chronic therapy whose baseline values were not obtained. • All patients starting or receiving long-term systemic glucocorticoid therapy should receive at least 1,500 mg elemental calcium and 800 to 1,200 units of vitamin D daily and practice a bone-healthy lifestyle.

More Related